NCT00973245View on ClinicalTrials.gov

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

PHASE2CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

January 31, 2007

Conditions

Atrial Fibrillation

Interventions

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

10mg od

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

15mg od

DRUG

Xarelto (Rivaroxaban, BAY59-7939)

20mg od

DRUG

Warfarin

Dose-adjusted warfarin based on target INR values

Trial Locations (11)

818-8516

Chikushino-shi

810-8798

Fukuoka

822-0026

Nōgata

078-8214

Asahikawa

651-0073

Kobe

665-0022

Takarazuka

511-0068

Kuwana

980-0803

Sendai

980-0871

Sendai

359-1141

Tokorozawa

141-0001

Shinagawa-ku

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT00973245 - BAY59-7939 in Atrial Fibrillation Once Daily (OD) | Biotech Hunter | Biotech Hunter